Under-the-radar biosimilars partners Formycon AG and Bioeq GmbH gained altitude by disclosing that they initiated a pivotal phase III trial of FYB201, a biosimilar of ranibizumab (Lucentis, Genentech Inc.), in patients with neovascular age-related macular degeneration (wet AMD).